Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 12/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12655684 | 0.92 | STAT3 (0.47) | STAT3PPARAPDK1PDK2PDK3 | |
| SCHEMBL1812818 | 0.87 | ACHE (0.43) | STAT3PDK1PDK2PDK3PDK4 | |
| SCHEMBL1810870 | 0.87 | PDK1 (0.41) | STAT3PDK1PDK2PDK3PDK4 | |
| SCHEMBL1815749 | 0.86 | PTPN11 (0.66) | PTPN11PTPROSTAT3PPARAKDM4E | |
| SCHEMBL1733846 | 0.84 | PTPN11 (0.51) | PTPN11PTPROSTAT3 | |
| SCHEMBL1736063 | 0.79 | PTPN11 (0.53) | PTPN11PTPROSTAT3 | |
| SCHEMBL1733819 | 0.79 | STAT3 (0.49) | PTPN11PTPROSTAT3 | |
| SCHEMBL1812842 | 0.79 | ALDH1A1 (0.34) | PTPN11PTPROSTAT3ALDH1A1POLB | |
| SCHEMBL12656005 | 0.78 | PDK1 (0.43) | STAT3PDK1PDK2PDK3PDK4 | |
| SCHEMBL12656075 | 0.78 | ACHE (0.45) | STAT3PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | claimed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | claimed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | claimed |
| EP-1756081-A1 | 1,1'-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2007-02-28 | — | — | EP | claimed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | claimed |
| WO-2005097773-A1 | 1,1’-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-10-20 | — | — | WO | claimed |
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | disclosed |
| EP-1756081-A1 | 1,1'-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2005097773-A1 | 1,1’-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | PTPRS, PTPRZ1, PTP4A1 | PTPN11 38/4885PTPRO 4/4885STAT3 2714/4885 |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | PTPN11 458/4885PTPRO 86/4885STAT3 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.